Table 2.
Medication | Dystonia Prevalence % (95%CI); Nr of studies and participants; I2 |
Akathisia Prevalence % (95%CI); Nr of studies and participants; I2 |
Parkinsonism Prevalence % (95%CI); Nr of studies and participants; I2 |
Tremor Prevalence % (95%CI); Nr of studies and participants; I2 |
---|---|---|---|---|
Amisulpride | 6.4% (1.0 to 32.1); 3 studies, 218 participants; I20 |
11.3% (6.5 to 19.0); 9 studies, 744 participants; I2 29.8 |
10.3% (4.2- to 23.2); 8 studies, 646 participants; I2 33.1 |
4.4% (1.4 to 13.1); 7 studies, 632 participants; I2 0 |
Aripiprazole | 5.5% (4.0 to 7.4); 41 studies, 1715 participants; I2 0 |
8.5% (7.2 to 10.1); 70 studies, 6552 participants; I2 0 |
7.2% (4.7 to 10.9); 15 studies, 857 participants; I2 0 |
6.1% (4.8 to 7.7); 53 studies, 2397 participants; I2 0 |
Asenapine | 2.8% (1.2 to 6.0); 1 study, 217 participants; I2 0 |
Not reported | 2.4% (0.2 to 25.6); 2 studies, 411 participants; I2 0 |
Not reported |
Chlorpromazine | 10.9% (5.2 to 21.3) 12 studies, 825 participants; I2 41 |
15.9% (12.4 to 20.2) 40 studies, 2087 participants; I2 4.8 |
21.1% (12.8 to 32.7) 20 studies, 910 participants; I2 34 |
18.4% (13.9 to 23.9) 29 studies, 1198 participants; I2 22.9 |
Clozapine | Not reported | 7.9% (2.7 to 20.7); 4 studies, 657 participants; I2 43.9 |
3.7% (0.3 to 35.3); 2 studies, 162 participants; I2 0 |
0.2% (0 to 1.4); 1 study, 490 participants; I2 0 |
Haloperidol | 16.5% (11.7 to 22.8) 24 studies; 838 participants; I2 7 |
24.8% (20.4 to 29.9) 33 studies, 1278 participants; I2 41 |
22.6% (13.3 to 35.7) 6 studies, 255 participants; I2 0 |
22% (15.6 to 30) 23 studies, 727 participants; I2 22.1 |
Olanzapine | 1.6% (1.0 to 2.8); 10 studies, 2599 participants; I2 10.5 |
8.7% (6.9 to 10.9); 27 studies, 4569 participants; I2 18.5 |
8.1% (5.5 to 11.8); 15 studies, 2636 participants; I2 37.5 |
7.9% (4.2 to 14.4); 12 studies, 1366 participants; I2 11.5 |
Paliperidone | 2.4% (0.1 to 33.0); 2 studies, 226 participants; I2 0 |
3.3% (1.8 to 6.0); 6 studies, 1496 participants; I2 0 |
Not reported | 2.7% (0.9 to 8.0); 7 studies, 1701 participants; I2 0 |
Quetiapine | 1.4% (0.7 to 2.8); 13 studies, 1642 participants; I2 0 |
5.2% (4.0 to 6.7); 35 studies, 3392 participants; I2 0 |
8.8% (4.6 to 16.3); 12 studies, 1585 participants; I2 23.6 |
6.0% (4.7 to 7.6); 20 studies, 1211 participants; I2 0 |
Risperidone | 5.0% (2.5 to 9.7); 11 studies, 1341 participants; I2 22.5 |
14.2% (11.4 to 17.6); 28 studies, 3263 participants; I2 6.9 |
12.1% (6.9 to 20.3); 16 studies, 1865 participants; I2 51.2 |
8.2% (6.1 to 11.1); 22 studies, 2699 participants; I2 16.6 |
Sulpiride | 15.3% (8.0 to 27.3); 6 studies, 146 participants; I2 11.9 |
16.4% (8.5 to 29.3); 8 studies, 211 participants; I2 30.3 |
29.3% (19.4 to 41.7); 7 studies, 193 participants; I2 14.7 |
28.2% (16.9 to 43.2); 4 studies, 93 participants; I2 21.0 |
Ziprasidone | 2.2% (1.0 to 4.8); 1 study, 271 participants; I2 0 |
8.3% (5.6 to 12.2); 6 studies, 832 participants; I2 1 |
10% (4.6 to 20.5); 1 study, 60 participants; I2 0 |
6.5 (2.2 to 17.8); 2 studies, 240 participants; I2 0 |